



Cite this: *Chem. Sci.*, 2025, **16**, 17939

All publication charges for this article have been paid for by the Royal Society of Chemistry

Received 2nd July 2025  
Accepted 22nd August 2025

DOI: 10.1039/d5sc04881h  
[rsc.li/chemical-science](http://rsc.li/chemical-science)

## Introduction

Coordination cages are discrete, three-dimensional, metal-organic assemblies with appreciable internal cavities capable of binding guest species.<sup>1</sup> Host-guest chemistry within these confined spaces has been exploited for binding anions,<sup>2</sup> pollutants,<sup>3</sup> drugs<sup>4</sup> and gases,<sup>5</sup> and for use in catalysis,<sup>6</sup> stabilisation of reactive species<sup>7</sup> and molecular separations.<sup>8</sup>

Most commonly, coordination cages are assembled from single, high-symmetry ligands, generally resulting in highly symmetrical architectures. More structurally sophisticated, low-symmetry cages, however, have the potential to exhibit bespoke properties and behaviours.<sup>9</sup> As such, there has been interest in developing strategies for the site-selective assembly of heteroleptic (mixed-ligand) cages<sup>10</sup> (Fig. 1a), and the orientation-selective assembly of cages from low-symmetry ligands<sup>11</sup> (Fig. 1b). In both instances, without sufficient driving force, statistical mixtures of isomers (and other assemblies) can form. Very recently, solutions to the challenge of incorporating low-symmetry ligands into heteroleptic cages (Fig. 1c) have also begun to be investigated.<sup>12</sup>

Geometric complementarity between ligands has been used to drive the formation of heteroleptic structures,<sup>13</sup> and similar design ideas have enabled the orientation-selective assembly of low-symmetry ligands.<sup>14</sup> Coordination sphere engineering – using non-covalent interactions, such as steric bulk or hydrogen bonding

(HB), to direct the coordination environment around metal ions<sup>15</sup> – is another strategy that has been successfully employed within both heteroleptic<sup>16</sup> and low-symmetry ligand systems.<sup>17</sup>

We recently investigated the self-assembly of homoleptic  $Pd_nL_{2n}$  assemblies from low-symmetry ligands that incorporated either quinoline or picoline donors in combination with unsubstituted pyridines.<sup>18</sup> Molecular modelling demonstrated that arranging the bulky quinoline/picoline donors *trans* to each other would give the lowest energy assemblies. Although experimentally this held true for ligands with picoline donors, quinolines unexpectedly favoured formation of *cis*- $Pd_nL_{2n}$  species. This difference in isomer selectivity was shown to be due to HB interactions between acidic protons of the coordinating donor units and solvent molecules. Such intermolecular non-covalent interactions within the second coordination spheres of the  $Pd^{(II)}$  ions of the cages could therefore override primary structural factors (*i.e.* steric bulk) in dictating self-assembly outcomes.

Within this previous work we reported a preliminary investigation of the heteroleptic cage  $Pd_2\mathbf{1AB}_2\mathbf{2AA}_2$  (see below) which, due to the unsymmetrical structure of ligand **1AB**, could exist as *syn*- and *anti*-isomers (Fig. 2). Chemical intuition, combined with molecular modelling, suggested the *anti*-isomer, with bulky quinoline groups situated far apart, would be lower in energy. The experimentally observed predominant formation of the more sterically encumbered *syn*-isomer, however, again suggested stabilising interactions in the second coordination sphere of the cage were superseding repulsive steric interactions in the first coordination sphere.

School of Chemistry, University of Birmingham, Molecular Sciences Building, Edgbaston, Birmingham B15 2TT, UK. E-mail: [j.e.m.lewis@bham.ac.uk](mailto:j.e.m.lewis@bham.ac.uk)






Fig. 1 Approaches to reduced symmetry coordination cages include (a) heteroleptic cages with combinations of ligands, (b) homoleptic cages assembled from low-symmetry ligands, and (c) heteroleptic cages assembled from (i) one or (ii) two low-symmetry ligands in which isomer selectivity can be tuned through structural design (this work).




Fig. 2 Self-assembly of low-symmetry ligands 1 and ligands 2/3/4 with Pd(II) ions forms *syn*- and *anti*-isomers, the latter of which are calculated (GFN2-xTB) to be lower in energy.

Stemming from this initial result, we were motivated to investigate a wider range of heteroleptic structures to observe the impact on isomer selectivity. In this regard, we wished to explore how isomer selectivity was influenced by (i) the identity of the symmetrical ligand; (ii) the combination of different heterocyclic donors on the unsymmetrical ligand, and (iii) the relative locations of the different donors within the cages. Finally, we also sought to achieve (iv) the selective formation of particular isomers of  $\text{Pd}_2\text{L}_2^{\text{A}}\text{L}_2^{\text{B}}$  cages assembled from two low-symmetry ligands. Gaining insights into how the, often subtle, balance of interactions that drive self-assembly outcomes can be shifted through design of structure and function will aid in the future development of structurally sophisticated metal-organic assemblies.

## Results and discussion

### System design and nomenclature

In this work we explored ligand scaffolds **1** and **2** (Fig. 2) that have previously been shown by Severin to be geometrically matched and able to undergo integrative self-assembly with Pd(II) ions to form *cis*- $[\text{Pd}_2\text{L}_2]^{\text{4}+}$  heteroleptic cages.<sup>19</sup> Ligands **3** and **4** are isostructural to **2** except that the core benzene unit is replaced with a pyridine and toluene, respectively. Each ligand has two N-heterocyclic donors. A two letter combination is used within each ligand name to signify which heterocycles are incorporated into the ligand: pyridine (**A**), quinoline (**B**), 2-picoline (**C**), 2-fluoropyridine (**D**), and 8-fluoroquinoline (**E**). Ligand **2AA**, for example, has a 1,3-diethynylbenzene core (**2**) and two pyridyl donors (**A**).

All ligands used in this work were synthesised using standard techniques and characterised by NMR spectroscopy and high resolution mass spectrometry (HR-MS). Details can be found in the SI.


All the cages in this work are tetracationic and prepared as the  $\text{BF}_4^-$  salts. For clarity, however, the charge and counterions are generally omitted from the main text. For example,  $[\text{Pd}_2\text{1AA}_2\text{2AA}_2](\text{BF}_4)_4$  may be written as  $\text{Pd}_2\text{1AA}_2\text{2AA}_2$ . Formation of the heteroleptic cages was confirmed by NMR spectroscopy, <sup>1</sup>H DOSY and electrospray ionisation (ESI) MS. Details can be found in the SI.

### Quinoline donor on diverging ligand

Ligand **1AB** incorporates two different donors: an unsubstituted pyridine (**A**), and a bulkier quinoline (**B**). We previously reported the self-assembly of heteroleptic cage  $\text{Pd}_2\text{1AB}_2\text{2AA}_2$  (Fig. 3a) in  $\text{CD}_3\text{CN}$  that formed predominantly as the intuitively more sterically encumbered *syn*-isomer.<sup>18</sup> This result is contrary to chemical intuition and molecular modelling (GFN2-xTB/MeCN<sup>20</sup> calculated in Orca<sup>21</sup>) of the cationic cage architecture alone (Fig. 2) which does not consider intermolecular interactions. This indicated that interactions beyond the primary structure of the cage were influencing isomer selectivity.

To explore the generality of this design, the self-assembly of **1AB** with alternative symmetric ligands **3AA** and **4AA** (featuring pyridyl and tolyl core units, respectively) was investigated. To





**Fig. 3** Partial  $^1\text{H}$  NMR spectra (400 MHz,  $\text{CD}_3\text{CN}$ , 298 K), with major *syn*-isomer peaks labelled, of (a)  $[\text{Pd}_2\text{1AB}_2\text{2AA}_2](\text{BF}_4)_4$ , (b)  $[\text{Pd}_2\text{1AB}_2\text{3-}\text{AA}_2](\text{BF}_4)_4$ , and (c)  $[\text{Pd}_2\text{1AB}_2\text{4AA}_2](\text{BF}_4)_4$ . (d) Partial NOESY spectrum (600 MHz,  $\text{CD}_3\text{CN}$ , 298 K) of  $[\text{Pd}_2\text{1AB}_2\text{2AA}_2](\text{BF}_4)_4$  with key peaks used to identify the *syn*- (s) and *anti*-isomers (a).

At this end, **1AB** and **3AA/4AA** were combined in a 1:1 ratio with  $[\text{Pd}(\text{CH}_3\text{CN})_4](\text{BF}_4)_2$  (used as the source of  $\text{Pd}(\text{n})$  throughout this work) in MeCN and equilibrated at 70 °C for 24 h. Formation of the desired  $[\text{Pd}_2\text{1}_2\text{3/4}_2]^{4+}$  cage structures was confirmed by ESI-MS, and the existence of both *syn*- and *anti*-isomers demonstrated by NMR spectroscopy (Fig. 3b and c).

The *syn*- and *anti*-isomers of these cages could be readily distinguished by NOESY (e.g. Fig. 3d); interactions between protons from the two ends of **1AB** (e.g.  $\text{H}_B \cdots \text{H}_I$ ) would only be expected from the antiparallel arrangement present in the *anti*-isomer (and were only observed for the minor species in each instance).

Both  $\text{Pd}_2\text{1AB23AA}_2$  and  $\text{Pd}_2\text{1AB}_2\text{4AA}_2$  formed the *syn*-isomer as the major product in similar amounts to the previously reported  $\text{Pd}_2\text{1AB}_2\text{2AA}_2$  ( $77 \pm 5\%$ ; Fig. S292). The identity of the core unit in ligand 2/3/4 was therefore shown not to materially affect isomer selectivity.

### Picoline donor on diverging ligand

Ligand **1AC** features a 2-picoly1 donor (**C**) in combination with an unsubstituted pyridine (**A**). In contrast to **1AB**, **1AC** does not possess acidic exohedral protons adjacent to the coordinating atoms of the bulky donor. Based on this, it was predicted that the heteroleptic cages with **2AA**, **3AA** and **4AA** would all form predominantly as the *anti*-isomers to avoid steric clash between the picoly1 units. It was somewhat surprising, therefore, that all




Fig. 4 (a) Partial  $^1\text{H}$  NMR spectrum (600 MHz,  $\text{CD}_3\text{CN}$ , 298 K), with major *syn*-isomer peaks labelled, of  $[\text{Pd}_2\text{1AC}_2\text{2AA}_2](\text{BF}_4)_4$ . (b) Partial NOESY spectrum (600 MHz,  $\text{CD}_3\text{CN}$ , 298 K) of  $[\text{Pd}_2\text{1AC}_2\text{2AA}_2](\text{BF}_4)_4$  with key peaks used to identify the *syn*- (s) and *anti*-isomers (a). (c) Visualisation of the coordination sphere sites of *anti*- and *syn*- $\text{Pd}_2\text{1AC}_2\text{2AA}_2$  cage isomers from geometry-optimised models (GFN2-xTB). (d) SCXRD structures of *syn*- $[\text{Pd}_2\text{1AC}_2\text{3AA}_2]^{4+}$ , showing endohedral  $\text{BF}_4^-$  counterion and exohedral  $\text{CH}_3\text{CN}$  solvent molecule interacting with the cage, and *anti*- $[\text{Pd}_2\text{1AC}_2\text{4AA}_2]^{4+}$ .

three of the cages also formed the *syn*-isomers as the major products ( $\sim 66 \pm 5\%$ ; Fig. S293) in CD<sub>3</sub>CN (Fig. 4a and b).

This selectivity was rationalised by comparing the coordination environments of the *syn*- and *anti*-isomers (Fig. 4c). A single picolyl unit on both faces of the *anti*-isomers is sufficient to significantly block interactions with both external coordination spheres of the cages. In contrast, the *syn*-isomers provide two different coordination spheres: one with two picolyl units, and a second, unencumbered, tetrapyridyl environment. The latter provides a single site with acidic protons  $H_B$  and  $H_b$  that could engage in HB interactions to stabilise the otherwise unfavourable accumulation of steric bulk at the other end of the cage. This idea was supported by single crystal X-ray diffraction

(SCXRD) studies (see below). As such, intermolecular non-covalent interactions on just one face of the cages are sufficient to overcome intramolecular steric interactions.

It is noted that  $\text{Pd}_2\mathbf{1AC}_2\mathbf{4AA}_2$  did not form exclusively as the heteroleptic assemblies. This was most likely the result of partial occlusion of the cavity by the tolyl methyl group, inhibiting access for anions/solvents necessary as templates.

The solid-state structures of  $\text{Pd}_2\mathbf{1AC}_2\mathbf{3AA}_2$  and  $\text{Pd}_2\mathbf{1AC}_2\mathbf{4AA}_2$  were determined by SCXRD (Fig. 4d). Intriguingly,  $\text{Pd}_2\mathbf{1AC}_2\mathbf{4AA}_2$  crystallised as the minor *anti*-isomer; this is presumably simply a facet of solid-state packing interactions. The structure of *syn*- $\text{Pd}_2\mathbf{1AC}_2\mathbf{3AA}_2$  revealed an acetonitrile molecule engaging in quadrifurcated hydrogen bond interactions with the tetrapyridyl face of the cage ( $\text{C}-\text{H}\cdots\text{N}$  2.62–2.72 Å), supporting the idea that such interactions could stabilise the *syn*-isomers in solution.<sup>22</sup>

### Alternative donor combinations on diverging ligand

To see how modifications to the donor units affected isomer selectivity, four variants of **1AB** were prepared (Fig. 5). **1BC** and **1BD** possess quinoline donors (**B**) combined with 2-picoline (**C**) or 2-fluoropyridine (**D**), respectively, whilst an 8-fluoroquinoline (**E**) donor was incorporated with an unsubstituted pyridine (**A**) into ligand **1AE**. In each of these ligands, compared to **1AB**, acidic protons on either the pyridine (**1BC** and **1BD**) or quinoline (**1AE**) were replaced with moieties that could not act as HB donors. Finally, **1CE**, with both picoline and 8-fluoroquinoline donors, was also synthesised.

In the case of  $\text{Pd}_2\mathbf{1BC}_2\mathbf{2AA}_2$ , a 1:1 mixture of the *syn*- and *anti*-isomers formed (Fig. S294), demonstrating a loss of

selectivity. Computational modelling revealed an insignificant ( $\sim 1 \text{ kJ mol}^{-1}$ ) energy difference between the two isomers. As such, it can be concluded that the sum of interaction energies in the first and second coordination spheres for each isomer are virtually identical.

Both  $\text{Pd}_2\mathbf{1BD}_2\mathbf{2AA}_2$  and  $\text{Pd}_2\mathbf{1AE}_2\mathbf{2AA}_2$  (Fig. 6a and b) formed predominantly ( $\sim 70\%$  each) as the *anti*-isomers (confirmed by NOESY analysis, *e.g.* Fig. 6c). As the substitution of hydrogen atoms for fluorine is widely regarded to have minimal impact on steric bulk,<sup>23</sup> additional steric hindrance beyond that of  $\text{Pd}_2\mathbf{1AB}_2\mathbf{2AA}_2$  would not seem to be a major factor in the observed inversion of isomer selectivity. The loss of acidic protons capable of forming HB interactions, combined with electrostatic repulsion between fluorine atoms, seem more likely to be




Fig. 6 Partial  $^1\text{H}$  NMR spectra (600 MHz,  $\text{CD}_3\text{CN}$ , 298 K) of (a)  $[\text{Pd}_2\mathbf{1BD}_2\mathbf{2AA}_2](\text{BF}_4)_4$  and (b)  $[\text{Pd}_2\mathbf{1AE}_2\mathbf{2AA}_2](\text{BF}_4)_4$  with major *anti*-isomer peaks labelled; partial NOESY spectrum (600 MHz,  $\text{CD}_3\text{CN}$ , 298 K) of  $[\text{Pd}_2\mathbf{1AE}_2\mathbf{2AA}_2](\text{BF}_4)_4$  with key peaks used to identify the major *anti*-isomer; (d) partial  $^1\text{H}$  NMR spectrum (400 MHz,  $\text{CD}_3\text{CN}$ , 298 K) of  $[\text{Pd}_2\mathbf{1CE}_2\mathbf{2AA}_2](\text{BF}_4)_4$  with major *anti*-isomer peaks labelled; (e) geometry-optimised models (GFN2-xTB) of the major *anti*-isomers of these cages.




Fig. 5 Summary of the observed *syn/anti* ratios in  $\text{CD}_3\text{CN}$  for combinations of low-symmetry ligand **1**, with various donor combinations, and symmetrical ligand **2AA**.



the major driving forces in promoting formation of the *anti*-isomer with these systems. As such,  $\text{Pd}_2\mathbf{1CE}_2\mathbf{2AA}_2$ , with no acidic exohedral protons on ligand **1**, was expected to form almost exclusively as the *anti*-isomer. Although this was indeed the major product ( $\sim 76\%$ ), the formation of significant amounts of the *syn*-isomer suggested that it was still possible to achieve substantive non-covalent interactions in the second coordination spheres of the *syn*-isomer.

The combinations of donor heterocycles investigated demonstrated varying isomer ratios could be achieved (24 to 77% *syn*). The energy-raising steric interactions between quinoline and picoline units in **1AB** and **1AC** in *syn*- $\text{Pd}_2\mathbf{1}_2\mathbf{2AA}_2$  could be offset by stabilising non-covalent interactions with the cages, whilst repulsive interactions between fluorinated heterocycles in **1BD** and **1AE** were sufficient to promote formation of *anti*-isomers. Indeed, inversion of the isomer selectivity between favouring *anti* and *syn* could be achieved through simply replacing a proton with a fluorine (**1AE** and **1BD** *vs.* **1AB**), demonstrating the potential for minor structural modifications to be used to drastically alter self-assembly profiles.

### Bulky donors on converging ligand

Having observed preferential formation of the *syn*-isomers of  $\text{Pd}_2\mathbf{1AB}_2\mathbf{2AA}_2$  and  $\text{Pd}_2\mathbf{1AC}_2\mathbf{2AA}_2$ , it was sought to determine whether there would be any impact on isomer selectivity from locating the bulky donors on the converging ligand, 2, instead of the diverging ligand. To this end, the heteroleptic cages assembled from **1AA** and unsymmetric **2AB**/**2AC** (Fig. 7a) were examined.

In contrast to the previously studied systems with **1AB** and **1AC**, NMR analysis (in  $\text{CD}_3\text{CN}$ ; Fig. 7b and c) of the  $\text{Pd}_2\mathbf{1AA}_2\mathbf{2AB}/\mathbf{2AC}_2$  cages showed the *anti*-isomers to be the major species for both ( $\sim 73\%$  (Fig. S298) and  $\sim 70\%$  (Fig. S299) with **2AB** and **2AC**, respectively). The solid-state structure of *anti*- $[\text{Pd}_2\mathbf{1AA}_2\mathbf{2AB}_2](\text{BF}_4)_4$  was also determined by SCXRD (Fig. 7d; the cage crystallised as a racemic mixture of the *P* and *M* enantiomers).<sup>24</sup> This subtle design change was thus sufficient to shift the balance between coordination sphere interactions driving the isomer selectivity. Geometry-optimised models of the *syn*- and *anti*-isomers of *cis*- $[\text{Pd}_2\mathbf{1AA}_2\mathbf{2AB}/\mathbf{2AC}_2]^{4+}$  suggested the former were more sterically crowded compared to the *cis*- $[\text{Pd}_2\mathbf{1AB}/\mathbf{1AC}_2\mathbf{2AA}_2]^{4+}$  systems, manifested as an increase in relative computed energy compared to the *anti*-isomers ( $\Delta E = 18.3$  and  $16.1\text{ kJ mol}^{-1}$  for the **2AB** and **2AC** cages, respectively). Thus, by slightly increasing the steric hindrance between bulky donors in the *syn*-isomers, simply through changing their location within the cages, this became the major driving force in isomer selectivity.

### Cages assembled from two low-symmetry ligands

Finally, the self-assembly of four possible cages from pairs of low-symmetry ligands, namely **1AB**, **1AC**, **2AB** and **2AC**, were investigated (Fig. 8a). For such *cis*- $\text{Pd}_2\mathbf{L}_2\mathbf{L}'_2$  systems there are six possible isomers (excluding enantiomers, **I**–**VI**; Fig. 8) depending upon the relative orientation of the two different low-symmetry ligands. Based on previous results it was




Fig. 7 (a) Structure of ligands **1AA**, **2AB** and **2AC**. Partial  $^1\text{H}$  NMR spectra (600 MHz,  $\text{CD}_3\text{CN}$ , 298 K), with major *anti*-isomer peaks labelled, of (b)  $[\text{Pd}_2\mathbf{1AA}_2\mathbf{2AB}_2]^{4+}$  and (c)  $[\text{Pd}_2\mathbf{1AA}_2\mathbf{2AC}_2]^{4+}$ . (d) Structures of *anti*-isomers of *P*- $[\text{Pd}_2\mathbf{1AA}_2\mathbf{2AB}_2]^{4+}$  (SCXRD) and *M*- $[\text{Pd}_2\mathbf{1AA}_2\mathbf{2AC}_2]^{4+}$  (GFN2-xTB geometry-optimised model).

anticipated that isomer **VI** would inherently be the lowest energy isomer based on steric arguments due to the *trans* arrangement of bulky donor units. This was supported by molecular modelling (GFN2-xTB) that showed **VI** to be the lowest energy isomer by at least  $13\text{ kJ mol}^{-1}$  for all four ligand combinations (Table S8–S11). Selective formation of this isomer would suggest minimising steric hindrance was the primary driving force dictating relative ligand orientation, whilst formation of other isomers would indicate alternative interactions were prominent.

For the combination of **1AB** and **2AB** an ill-defined mixture formed in  $\text{CD}_3\text{CN}$  that defied analysis. Repeating the self-assembly in  $d_6\text{-DMSO}$  resulted in more tractable NMR data (Fig. 8b). Signals in the  $^1\text{H}$  NMR spectrum could be readily identified for the homoleptic assembly of **2AB** ( $\sim 30\%$  yield). Two additional sets of signals, however, belonged to  $\text{Pd}_2\mathbf{1AB}_2\mathbf{2AB}_2$  cage isomers (the formation of which was confirmed






Fig. 8 (a) The selective formation of particular isomers of Pd<sub>2</sub>L<sub>2</sub>-type cages (GXN2-xTB geometry-optimised models shown) from combinations of ligands 1AB/1AC and 2AB/2AC was observed. Partial <sup>1</sup>H NMR spectra (600 MHz, 298 K) of (b) [Pd<sub>2</sub>1AB<sub>2</sub>2AB<sub>2</sub>](BF<sub>4</sub>)<sub>4</sub> (d<sub>6</sub>-DMSO) with peaks assigned to major isomer V labelled (# = minor isomer; \* = [Pd<sub>2</sub>2AB<sub>2</sub>]<sup>4+</sup>); and (c) [Pd<sub>2</sub>1AC<sub>2</sub>2AC<sub>2</sub>](BF<sub>4</sub>)<sub>4</sub>, (d) [Pd<sub>2</sub>1AB<sub>2</sub>2AC<sub>2</sub>](BF<sub>4</sub>)<sub>4</sub>, and (e) [Pd<sub>2</sub>1AC<sub>2</sub>2AB<sub>2</sub>](BF<sub>4</sub>)<sub>4</sub> (all CD<sub>3</sub>CN) with peaks assigned to major product, isomer VI, labelled.

by ESI-MS) forming approximately 35% and 13% of the mixture. NOESY allowed assignment of the major cage isomer as V. As such, preferential formation of a *cis* arrangement of quinoline donors was observed, suggesting that interactions in the second coordination sphere were the major drivers of isomer selectivity for this system.

A single major species was observed to form in ~62% yield (Fig. S301) from the equilibrated 1:1:1 mixture of 1AC, 2AC and [Pd(CH<sub>3</sub>CN)<sub>4</sub>](BF<sub>4</sub>)<sub>2</sub> in CD<sub>3</sub>CN (Fig. 8c). ESI-MS confirmed the anticipated formulation of the assembled heteroleptic structure. NOE coupling (Fig. 9) of both methyl groups (H<sub>G</sub> of 1AC and H<sub>k</sub> of 2AC) with both external *ortho* pyridyl protons (H<sub>B</sub> of 1AC and H<sub>b</sub> of 2AC) was consistent with only two possible

isomers, with the picolyl units arranged either *cis* (III) or *trans* (VI) to each other. NOE coupling (Fig. 9 inset) exclusively between internal protons H<sub>A</sub> and H<sub>I</sub> and between H<sub>H</sub> and H<sub>a</sub>




Fig. 9 Partial NOESY spectrum (600 MHz, CD<sub>3</sub>CN, 298 K) of [Pd<sub>2</sub>1AC<sub>2</sub>2AC<sub>2</sub>](BF<sub>4</sub>)<sub>4</sub> identifying the major product as isomer VI.



(and not  $H_A \cdots H_a$  or  $H_H \cdots H_l$ ) and the lack of coupling between  $H_b$  and  $H_B$ , however, confirmed that the major product formed was isomer **VI**. Thus, alleviation of steric hindrance appeared to be the primary driving force in isomer selectivity.

Similarly, both  $Pd_2\mathbf{1AB}_2\mathbf{2AC}_2$  and  $Pd_2\mathbf{1AC}_2\mathbf{2AB}_2$  (Fig. 8d and e, respectively) formed isomer **VI** as the major species (each ~45% yield; Fig. S302 and S303), with pairs of quinoline and picoline donors arranged *trans* to each other on opposite faces of the cage. Again, this suggested minimising steric interactions was the major driving force at play.

These results are consistent with the earlier systems examined. For alternative isomers than **VI** to be formed, suitable sites for non-covalent interactions would need to be accessible. This is possible with isomer **I**, but having all four bulky heterocycles on one face raises the system energy too much ( $\Delta E > 40$  kJ mol<sup>-1</sup> relative to **VI**). Isomers that provide a *syn* orientation of **2AB** or **2AC** (**II** and **V**) were previously shown to be relatively unfavourable, while isomers **III** and **IV** would place picoline and quinoline units adjacent to each other, inhibiting access to the acidic quinolyl protons. Thus, the preferential formation of isomer **VI** can be rationalised based on the principles established in this work.

## Conclusions

We have investigated the self-assembly of heteroleptic  $Pd_2L_2^{A-}L_2^{B-}$ -type coordination cages from low-symmetry ligands incorporating different combinations of heterocyclic donors. Integrative self-assembly of the two ligands is directed by geometric complementarity, while the relative orientation of the low-symmetry scaffolds (*i.e.* isomer selectivity) is driven by coordination sphere interactions. Isomer selectivity could be changed by relatively subtle structural variations, including exchanging a proton for a fluorine atom, or changing the relative locations of heterocycles within the cage structures.

In the case of cages assembled with one low-symmetry ligand, this allowed formation of cages primarily as the *syn*-isomer (up to ~77%), primarily as the *anti*-isomer (up to ~76%), or an approximately equal mixture of the two. Selective formation of particular isomers of heteroleptic cages assembled from two low-symmetry ligands (up to ~62%) was also demonstrated, the assembly of which could be rationally explained from the underlying design principles delineated from this work. As such, we have shown how ligand design can be used to promote interactions in the first or second coordination spheres as the major drivers of isomer selectivity.

Through the combined computational and experimental investigations of the systems explored, it has been possible to gain insight into how structural designs can modulate the relative impact of both intramolecular (first coordination sphere) and intermolecular (second coordination sphere) interactions in directing self-assembly outcomes. In the continued pursuit of developing ever more structurally sophisticated metallo-supramolecular assemblies, understanding (i) how different directing strategies can be used in a synergistic manner, and (ii) the effects of environment (*e.g.* solvent) on thermodynamic self-assembly processes, will enable the design

of increasingly structurally and functionally advanced, precision-engineered systems capable of exhibiting bespoke and nuanced properties and behaviours.

## Author contributions

PM carried out the synthesis, characterisation and data analysis. PM and LM collected and analysed the SCXRD data. JEML conceived and directed the project, secured funding, performed molecular modelling, aided data analysis and wrote the manuscript. All authors contributed to editing and approved the final manuscript.

## Conflicts of interest

There are no conflicts to declare.

## Data availability

CCDC 2390755 ( $[Pd_2\mathbf{1AA}_2\mathbf{2AB}_2](BF_4)_4$ ), 2390756 ( $[Pd_2\mathbf{1AC}_2\mathbf{4AA}_2](BF_4)_4$ ) and 2390758 ( $[Pd_2\mathbf{1AC}_2\mathbf{3AA}_2](BF_4)_4$ ) contain the supplementary crystallographic data for this paper.<sup>25a-c</sup>

The data supporting this article have been included as part of the SI. See DOI: <https://doi.org/10.1039/d5sc04881h>.

## Acknowledgements

We thank Dr Cécile Le Duff for assistance with the collection of NMR data, Dr Christopher Williams for the collection of MS data, and HWB-NMR staff at the University of Birmingham for providing open access to their NMR spectrometers. Dr Dan Preston (ANU) is thanked for useful discussions and optimism. This work was supported by the Royal Society (URF\R1\221740 and RF\ERE\221016) and the University of Birmingham (including a PhD studentship to PM). JEML is a Royal Society University Research Fellow.

## References

- (a) A. Schmidt, A. Casini and F. E. Kühn, *Coord. Chem. Rev.*, 2014, **275**, 19; (b) T. R. Cook and P. J. Stang, *Chem. Rev.*, 2015, **115**, 7001; (c) M. D. Ward, C. A. Hunter and N. H. Williams, *Acc. Chem. Res.*, 2018, **51**, 2073; (d) D. Zhang, T. K. Ronson and J. R. Nitschke, *Acc. Chem. Res.*, 2018, **51**, 2423; (e) B. S. Pilgrim and N. R. Champness, *ChemPlusChem*, 2020, **85**, 1842; (f) S. Lee, H. Jeong, D. Nam, M. S. Lah and W. Choe, *Chem. Soc. Rev.*, 2021, **50**, 528; (g) J. E. M. Lewis, *Chem. Commun.*, 2022, **58**, 13873; (h) T. Teteishi, M. Yoshimura, S. Tokuda, F. Matsuda, D. Fujita and S. Furukawa, *Coord. Chem. Rev.*, 2022, **467**, 214612; (i) A. J. McConnell, *Chem. Soc. Rev.*, 2022, **51**, 2957; (j) R. Banerjee, D. Chakraborty and P. S. Mukherjee, *J. Am. Chem. Soc.*, 2023, **145**, 7692; (k) S. Sharma, M. Sarkar and D. K. Chand, *Chem. Commun.*, 2023, **59**, 535; (l) C. J. T. Cox, J. Hale, P. Molinska and J. E. M. Lewis, *Chem. Soc. Rev.*, 2024, **53**, 10380.



2 (a) R. Custelcean, *Chem. Soc. Rev.*, 2014, **43**, 1823; (b) D. Preston, K. M. Patil, A. T. O'Neil, R. A. S. Vasdev, J. A. Kitchen and P. E. Kruger, *Inorg. Chem. Front.*, 2020, **7**, 2990; (c) B. J. J. Timmer and T. J. Mooibroek, *Chem. Commun.*, 2021, **57**, 7184; (d) S. J. Allison, J. Bryk, C. J. Clemett, R. A. Faulkner, M. Gingner, H. B. S. Griffiths, J. Harmer, P. J. Owen-Lynch, E. Pinder, H. Wurdak, R. M. Phillips and C. R. Rice, *Nat. Commun.*, 2021, **12**, 3898; (e) V. Sivalingam, S. Krishnaswamy and D. K. Chand, *Chem.-Eur. J.*, 2023, **29**, e202300891; (f) S. Sudan, D. W. Chen, C. Berton, F. Fadaei-Tirani and K. Severin, *Angew. Chem., Int. Ed.*, 2023, **62**, e202218072; (g) W.-L. Jiang, B. Huang, X.-L. Zhao, X. Shi and H.-B. Yang, *Chem.*, 2023, **9**, 2655; (h) Y.-L. Lai, m. Xie, X.-C. Zhou, X.-Z. Wang, X.-W. Zhu, D. Luo, X.-P. Zhou and D. Li, *Angew. Chem., Int. Ed.*, 2024, **63**, e202402829; (i) J. I. Virtue, S. Tsoukatos, M. R. Johnston and W. M. Bloch, *Chem. Sci.*, 2024, **15**, 19119.

3 (a) E. G. Percástegui, *Chem. Commun.*, 2022, **58**, 5055; (b) I. A. Riddell, M. M. J. Smulders, J. K. Clegg and J. R. Nitschke, *Chem. Commun.*, 2011, **47**, 457; (c) C. G. P. Taylor, J. R. Piper and M. D. Ward, *Chem. Commun.*, 2016, **52**, 6225; (d) S. Ganta and D. K. Chand, *Inorg. Chem.*, 2018, **57**, 3634; (e) A. Platzek, S. Juber, C. Yurtseven, S. Hasegawa, L. Schneider, C. Drechsler, K. E. Ebbert, R. Rudolf, Q.-Q. Yan, J. J. Holstein, L. V. Schäfer and G. H. Clever, *Angew. Chem., Int. Ed.*, 2022, **61**, e202209305; (f) T. K. Ronson, J. P. Carpenter and J. R. Nitschke, *Chem.*, 2022, **8**, 557.

4 (a) J. E. M. Lewis, E. L. Gavey, S. A. Cameron and J. D. Crowley, *Chem. Sci.*, 2012, **3**, 778; (b) Y.-R. Zheng, K. Suntharalingam, T. C. Johnstone and S. L. Lippard, *Chem. Sci.*, 2015, **6**, 1189; (c) A. Schmidt, V. Molano, M. Hollering, A. Pöthig, A. Casini and F. E. Kühn, *Chem.-Eur. J.*, 2016, **22**, 2253; (d) Y. Fang, X. Lian, Y. Huang, G. Fu, Z. Xiao, Q. Wang, B. Nan, J.-P. Pellois and H.-C. Zhou, *Small*, 2018, **14**, 1802709; (e) F. J. Rizzuto, J. P. Carpenter and J. R. Nitschke, *J. Am. Chem. Soc.*, 2019, **141**, 9087; (f) G. Li, T. K. Ronson, R. Lavendomme, Z. Huang, C. Fuertes-Espinosa, D. Zhang and J. R. Nitschke, *Chem.*, 2023, **9**, 1549; (g) Y.-H. Huang, Y.-L. Lu, Z.-M. Cao, X.-D. Zhang, C.-H. Liu, H.-S. Xu and C.-Y. Su, *J. Am. Chem. Soc.*, 2024, **146**, 21677; (h) G. Montà-González, D. Bastante-Rodríguez, A. García-Fernández, P. J. Lusby, R. Martínez-Máñez and V. Martí-Centelles, *Chem. Sci.*, 2024, **15**, 10010.

5 (a) A. J. Gosselin, C. A. Rowland and E. D. Bloch, *Chem. Rev.*, 2020, **120**, 8987; (b) Q.-W. Zeng, L. Hu, Y. Niu, D. Wang, Y. Kang, H. Jia, W.-T. Dou and L. Xu, *Chem. Commun.*, 2024, **60**, 3469; (c) J. Roukala, J. Zhu, C. Giri, K. Rissanen, P. Lantto and V.-V. Telkki, *J. Am. Chem. Soc.*, 2015, **137**, 2411; (d) D. Preston, K. F. White, J. E. M. Lewis, R. A. S. Vasdev, B. F. Abrahams and J. D. Crowley, *Chem.-Eur. J.*, 2017, **23**, 10559; (e) J. S. Wright, A. J. Metherell, W. M. Cullen, J. R. Piper, R. Dawson and M. D. Ward, *Chem. Commun.*, 2017, **53**, 4398; (f) C. A. Rowland, G. R. Lorzing, A. J. Gosselin, B. A. Trump, G. P. A. Yap, C. M. Brown and E. D. Bloch, *J. Am. Chem. Soc.*, 2018, **140**, 11153; (g) J.-L. Zhu, D. Zhang, T. K. Ronson, W. Wang, L. Xu, H.-B. Yang and J. R. Nitschke, *Angew. Chem., Int. Ed.*, 2021, **60**, 11789.

6 (a) C. J. Brown, F. D. Toste, R. G. Bergman and K. N. Raymond, *Chem. Rev.*, 2015, **115**, 3012; (b) Y. Xue, X. Hang, J. Ding, B. Li, R. Zhu, H. Pang and Q. Xu, *Coord. Chem. Rev.*, 2021, **430**, 213656; (c) T. K. Piskorz, V. Martí-Centelles, R. L. Spicer, F. Duarte and P. J. Lusby, *Chem. Sci.*, 2023, **14**, 11300; (d) M. Yoshizawa, M. Tamura and M. Fujita, *Science*, 2006, **312**, 251; (e) M. D. Pluth, R. G. Bergman and K. N. Raymond, *Science*, 2007, **316**, 85; (f) J. L. Bolliger, A. M. Belenguer and J. R. Nitschke, *Angew. Chem., Int. Ed.*, 2013, **52**, 7958; (g) X. Jing, C. He, Y. Yang and C. Duan, *J. Am. Chem. Soc.*, 2015, **137**, 3967; (h) V. Martí-Centelles, A. L. Lawrence and P. J. Lusby, *J. Am. Chem. Soc.*, 2018, **140**, 2862; (i) W. Cullen, A. J. Metherell, A. B. Wragg, C. G. P. Taylor, N. H. Williams and M. D. Ward, *J. Am. Chem. Soc.*, 2018, **140**, 2821; (j) A. Paul, M. A. Shipman, D. Y. Onabule, S. Sproules and M. D. Symes, *Chem. Sci.*, 2021, **12**, 5082; (k) S. M. Bierschenk, J. Y. Pan, N. S. Settineri, U. Warzok, R. G. Bergman, K. N. Raymond and F. D. Toste, *J. Am. Chem. Soc.*, 2022, **144**, 11425; (l) E. O. Bobylev, J. Ruijter, D. A. Poole III, S. Mathew, B. de Bruin and J. N. H. Reek, *Angew. Chem., Int. Ed.*, 2023, **62**, e202218162; (m) R. G. DiNardi, S. Rasheed, S. S. Capomolla, M. H. Chak, I. A. Middleton, L. K. Macreadie, J. P. Violi, W. A. Donald, P. J. Lusby and J. E. Beves, *J. Am. Chem. Soc.*, 2024, **146**, 21196.

7 (a) M. Yoshizawa, T. Kusukawa, M. Fujita and K. Yamaguchi, *J. Am. Chem. Soc.*, 2000, **122**, 6311; (b) P. Mal, B. Breiner, K. Rissanen and J. R. Nitschke, *Science*, 2009, **324**, 1697; (c) M. Yamashina, Y. Sei, M. Akita and M. Yoshizawa, *Nat. Commun.*, 2014, **5**, 4662; (d) M. Canton, A. B. Grommet, L. Pesce, J. Gemen, S. Li, Y. Diskin-Posner, A. Credi, G. M. Pavan, J. Andréasson and R. Klajn, *J. Am. Chem. Soc.*, 2020, **142**, 14557; (e) S. Hasegawa, S. L. Meichsner, J. J. Holstein, A. Baksi, M. Kasanmascheff and G. H. Clever, *J. Am. Chem. Soc.*, 2021, **143**, 9718; (f) R. Sumida, Y. Tanaka, K. Niki, Y. Sei, S. Toyota and M. Yoshizawa, *Chem. Sci.*, 2021, **12**, 9946; (g) M. Ray, S. Krishnaswamy, A. K. Pardhan and D. K. Chand, *Chem. Mater.*, 2023, **35**, 6702; (h) J. C. Dorrat, R. J. Young, C. G. P. Taylor, M. B. Tipping, A. J. Blok, D. R. Turner, A. I. McKay, S. Ovenden, M. D. Ward, G. H. Dennison and K. L. Tuck, *Dalton Trans.*, 2023, **52**, 11802.

8 (a) D. Zhang, T. K. Ronson, Y.-Q. Zou and J. R. Nitschke, *Nat. Rev. Chem.*, 2021, **5**, 168; (b) C. Zhu, H. Tang, K. Yang, Y. Fang, K.-Y. Wawng, Z. Xiao, X. Wu, Y. Li, J. A. Powell and H.-C. Zhou, *J. Am. Chem. Soc.*, 2021, **143**, 12560; (c) P.-F. Cui, X.-R. Liu, Y.-J. Lin, Z.-H. Li and G.-X. Jin, *J. Am. Chem. Soc.*, 2022, **144**, 6558; (d) L.-J. Wang, S. Bai and Y.-F. Han, *J. Am. Chem. Soc.*, 2022, **144**, 16191; (e) D. Chakraborty, R. Saha, J. K. Clegg and P. S. Mukherjee, *Chem. Sci.*, 2022, **13**, 11764; (f) C.-W. Zhou, X.-Z. Wang, M. Xie, R.-Q. Xia, D. Luo, Z.-X. Lian, G.-H. Ning, W. Lu, X.-P. Zhou and D. Li, *Angew. Chem., Int. Ed.*, 2023, **62**,



e202315020; (g) A. Ghosh, J. Pruchyathamkorn, C. F. Espinosa and J. R. Nitschke, *J. Am. Chem. Soc.*, 2024, **146**, 2568.

9 (a) S. Pullen, J. Tessarolo and G. H. Clever, *Chem. Sci.*, 2021, **12**, 7269; (b) C. T. McTernan, J. A. Davies and J. R. Nitschke, *Chem. Rev.*, 2022, **122**, 10393; (c) J. E. M. Lewis, *Trends Chem.*, 2023, **5**, 717; (d) Z. T. Avery, J. L. Algar and D. Preston, *Trends Chem.*, 2024, **6**, 352.

10 (a) W. M. Bloch and G. H. Clever, *Chem. Commun.*, 2017, **53**, 8506; (b) D. Bardhan and D. K. Chand, *Chem.-Eur. J.*, 2019, **25**, 12241.

11 (a) J. E. M. Lewis and J. D. Crowley, *ChemPlusChem*, 2020, **85**, 815; (b) D. Tripathy, N. B. Debata, K. C. Naik and H. S. Sahoo, *Coord. Chem. Rev.*, 2022, **456**, 214396.

12 (a) D. Preston and J. D. Evans, *Angew. Chem., Int. Ed.*, 2023, **62**, e202314378; (b) M. Parbin, V. Sivalingam and D. K. Chand, *Angew. Chem., Int. Ed.*, 2024, **63**, e202410219; (c) A. Kumar, S. Krishnaswamy and D. K. Chand, *Angew. Chem., Int. Ed.*, 2025, **64**, e202416332; (d) M. R. Black, S. Bhattacharyya, S. P. Argent and B. S. Pilgrim, *J. Am. Chem. Soc.*, 2024, **146**, 28233; (e) S. Sharma, D. John and D. K. Chand, *Chem.-Asian J.*, 2025, **20**, e202401941; (f) H. Yu, Z. Guo, J. Tang, N. Han, J. Shi, M. Li, H. Zhang and M. Wang, *Chem. Sci.*, 2025, **16**, 6114.

13 (a) J.-R. Li and H.-C. Zhou, *Nat. Chem.*, 2010, **2**, 893; (b) Q.-F. Sun, S. Sato and M. Fujita, *Angew. Chem., Int. Ed.*, 2014, **53**, 13510; (c) W. M. Bloch, Y. Abe, J. J. Holstein, C. M. Wandtke, B. Dittrich and G. H. Clever, *J. Am. Chem. Soc.*, 2016, **138**, 13750; (d) W. M. Bloch, J. J. Holstein, W. Hiller and G. H. Clever, *Angew. Chem., Int. Ed.*, 2017, **56**, 8285; (e) J. A. Findlay, K. M. Patil, M. G. Gardiner, H. I. MacDermott-Opeskin, M. L. O'Mara, P. E. Kruger and D. Preston, *Chem.-Asian J.*, 2022, **17**, e202200093; (f) K. Wu, J. Tessarolo, A. Baksi and G. H. Clever, *Angew. Chem., Int. Ed.*, 2022, **61**, e202205727; (g) K. Wu, E. Benchimol, A. Baksi and G. H. Clever, *Nat. Chem.*, 2024, **16**, 584.

14 (a) D. Ogata and J. Yuasa, *Angew. Chem., Int. Ed.*, 2019, **58**, 18424; (b) J. E. M. Lewis, A. Tarzia, A. J. P. White and K. E. Jelfs, *Chem. Sci.*, 2020, **11**, 677; (c) S. S. Mishra, S. V. K. Kompella, S. Krishnaswamy, S. Balasubramanian and D. K. Chand, *Inorg. Chem.*, 2020, **59**, 12884; (d) J. E. M. Lewis, *Chem.-Eur. J.*, 2021, **27**, 44454; (e) R.-J. Li, A. Marcus, F. Fadaei-Tirani and K. Severin, *Chem. Commun.*, 2021, **57**, 10023; (f) H. Yu, J. Li, C. Shan, T. Lu, X. Jiang, J. Shi, L. Wojtas, H. Zhang and M. Wang, *Angew. Chem., Int. Ed.*, 2021, **60**, 26523; (g) A. Tarzia, J. E. M. Lewis and K. E. Jelfs, *Angew. Chem., Int. Ed.*, 2021, **60**, 20879; (h) R.-J. Li, A. Tarzia, V. Posligha, K. E. Jelfs, N. Sanchez, A. Marcus, A. Baksi, G. H. Clever, F. Fadaei-Tirani and K. Severin, *Chem. Sci.*, 2022, **13**, 11912; (i) J. de Montmollin, A. B. Solea, D. W. Chen, F. Fadaei-Tirani and K. Severin, *Inorg. Chem.*, 2024, **63**, 4583; (j) S. E. Walker, N. Kyrtzis, D. U. Sawant, A. I. McKay, K. L. Tuck and D. R. Turner, *Inorg. Chem.*, 2024, **63**, 15659; (k) J. A. Gome, Z. T. Avery, N. R. Lawson, O. G. Stansfield, J. D. Evans, M. G. Gardiner, T. U. Connell and D. Preston, *Angew. Chem., Int. Ed.*, 2025, **64**, e202503473.

15 M. Yoshizawa, M. Nagao, K. Kumzawa and M. Fujita, *J. Organomet. Chem.*, 2005, **690**, 5383.

16 (a) D. Preston, J. E. Barnsley, K. C. Gordon and J. D. Crowley, *J. Am. Chem. Soc.*, 2016, **138**, 10578; (b) R. Zhu, W. M. Bloch, J. J. Holstein, S. Mandal, L. V. Schäfer and G. H. Clever, *Chem.-Eur. J.*, 2018, **24**, 12734; (c) R.-J. Li, J. Tessarolo, H. Lee and G. H. Clever, *J. Am. Chem. Soc.*, 2021, **143**, 3865; (d) B. Chen, J. J. Holstein, A. Platzek, L. Schneider, K. Wu and G. H. Clever, *Chem. Sci.*, 2022, **13**, 1829; (e) Y. Liu, S.-H. Liao, W.-T. Dai, Q. Bai, S. Lu, H. Wang, X. Li, Z. Zhang, P. Wang, W. Lu and Q. Zhang, *Angew. Chem., Int. Ed.*, 2023, **62**, e202217215; (f) Z. Guo, H. Yu, J. Shi, N. Han, G. Wu, H. Zhang, B. Li and M. Wang, *Angew. Chem., Int. Ed.*, 2025, **64**, e202425369; (g) Y.-M. Tan, L.-M. Zhang, Q. Bai, Z. Zhang, P. Wang and Q. Zhang, *Chem. Sci.*, 2025, **16**, 4625.

17 (a) R. A. S. Vasdev, D. Preston, C. A. Casey-Stevens, V. Martí-Centelles, P. J. Lusby, A. L. Garden and J. D. Crowley, *Inorg. Chem.*, 2023, **62**, 1833; (b) B. E. Barber, E. M. G. Jamieson, L. E. M. White and C. T. McTernan, *Chem.*, 2024, **10**, 2792.

18 P. Molinska, A. Tarzia, L. Male, K. E. Jelfs and J. E. M. Lewis, *Angew. Chem., Int. Ed.*, 2023, **62**, e202315451.

19 R.-J. Li, J. de Montmollin, F. Fadaei-Tirani, R. Scopelliti and K. Severin, *Dalton Trans.*, 2023, **52**, 6451.

20 C. Bannwarth, S. Ehlert and S. Grimme, *J. Chem. Theory Comput.*, 2019, **153**, 1652.

21 (a) F. Neese, *Wiley Interdiscip. Rev.: Comput. Mol. Sci.*, 2012, **2**, 73; (b) F. Neese, *Wiley Interdiscip. Rev.: Comput. Mol. Sci.*, 2018, **8**, e1327.

22 The effects of different solvents on isomer distributions for  $Pd_2^{+}AB_2^{2-}AA_2^{-}$  and  $Pd_2^{+}AC_2^{2-}AA_2^{-}$ , and differences in interactions of  $^{\pm}OTs$  anions with the *syn*- and *anti*-isomers, are described in the SI Section S4.

23 D. O'Hagan, *Chem. Soc. Rev.*, 2008, **37**, 308.

24 M. C. Biagini, M. Ferrari, M. Lanfranchi, L. Marchiò and M. A. Pellinghelli, *J. Chem. Soc., Dalton Trans.*, 1999, 1575.

25 (a) P. Molinska, L. Male and J. E. M. Lewis, CCDC [2390755]: Experimental Crystal Structure Determination, 2025, DOI: [10.5517/ccdc.csd.cc2l7s4s](https://doi.org/10.5517/ccdc.csd.cc2l7s4s); (b) P. Molinska, L. Male and J. E. M. Lewis, CCDC [2390756]: Experimental Crystal Structure Determination, 2025, DOI: [10.5517/ccdc.csd.cc2l7s5t](https://doi.org/10.5517/ccdc.csd.cc2l7s5t); (c) P. Molinska, L. Male and J. E. M. Lewis, CCDC [2390758]: Experimental Crystal Structure Determination, 2025, DOI: [10.5517/ccdc.csd.cc2l7s7w](https://doi.org/10.5517/ccdc.csd.cc2l7s7w).

